N-(7-(Methylsulfonamido)-4-oxo-6-phenoxy-4H-chromen-3-yl)formamide CAS 123663-49-0

Product Description:

Product Name: N-(7-(Methylsulfonamido)-4-oxo-6-phenoxy-4H-chromen-3-yl)formamide CAS NO: 123663-49-0                                          

Synonyms:

N-(3-Formamido-4-oxo-6-phenoxy-4H-chromen-7-yl)methanesulfonamide;

3-(Formylamino)-7-(methylsulfonylamino)-6-phenoxy-4H-1-benzopyran-4-one;

IguratiMod (T 614);

Chemical & Physical Properties:

Appearance: White powder

Assay :≥99.0%

Density: 1.52 g/cm3

Boiling Point: 580.6℃ at 760 mmHg

Melting Point: 238.0 to 242.0℃

Flash Point: 304.9℃

Refractive Index: 1.673

Vapor Pressure: 1.8E-13mmHg at 25℃

Safety Information:

HS Code: 2935009090

Iguratimod is an anti-inflammatory drug for the treatment of rheumatoid arthritis. It is approved for use in China and Japan, and is sold by Eisai and Toyama Chemical. Its mechanism of action involves the suppression of nuclear factor-kappa B (NF-κB). Iguratimod acts as an anti-inflammatory agent, used primarily in the treatment of rheumatoid arthritis.

Iguratimod, which was discovered by Toyama Pharmaceuticals and jointly co-developed with Eisai in Japan, was approved by the PMDA (Pharmaceuticals and Medical Devices Agency) of Japan on June 29, 2012 for the treatment of rheumatoid arthritis. This drug was also independently developed by Simcere Pharmaceutical Group and is marked as Iremod® in China. The drug exhibited inhibitory effects on granuloma inflammation, and was shown to be efficacious for the prevention of joint destruction in adjuvant arthritis.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.